Pharmacodynamic Analysis of the Microbiological Efficacy of Telithromycin in Patients with Community-Acquired Pneumonia

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.44, Iss.3, 2005-01, pp. : 317-329

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benefit-Risk Assessment of Telithromycin in the Treatment of Community-Acquired Pneumonia

By Brown Steven D.

Drug Safety, Vol. 31, Iss. 7, 2008-01 ,pp. : 561-575

Adis International

Access to resources Recommend Favorite

Improving Outcomes of Elderly Patients with Community-Acquired Pneumonia

By Gutiérrez Félix Masiá Mar

Drugs & Aging, Vol. 25, Iss. 7, 2008-01 ,pp. : 585-610

Adis International

Access to resources Recommend Favorite

Efficacy, Onset of Action and Tolerability of Moxifloxacin in Patients with Community-Acquired Pneumonia: Results of a Postmarketing Surveillance Study

By Landen H.

Clinical Drug Investigation, Vol. 21, Iss. 12, 2001-12 ,pp. : 801-811

Adis International

Access to resources Recommend Favorite

Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin

By Nicolau David P

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 229-235

Informa Healthcare

Access to resources Recommend Favorite

Tigecycline: In Community-Acquired Pneumonia

By McKeage Kate Keating Gillian M.

Drugs, Vol. 68, Iss. 18, 2008-01 ,pp. : 2633-2644

Adis International

Access to resources Recommend Favorite